C4 Therapeutics (CCCC) Set to Post Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1945) per share and revenue of $8.82 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 12:30 PM ET.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. The business had revenue of $6.64 million during the quarter, compared to analyst estimates of $4.00 million. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%. On average, analysts expect C4 Therapeutics to post ($0.81) EPS for the current fiscal year and ($0.95) EPS for the next fiscal year.

C4 Therapeutics Price Performance

Shares of C4 Therapeutics stock opened at $3.39 on Thursday. The firm has a 50 day simple moving average of $3.35 and a 200 day simple moving average of $3.19. C4 Therapeutics has a fifty-two week low of $1.69 and a fifty-two week high of $5.17. The firm has a market cap of $417.05 million, a P/E ratio of -3.39 and a beta of 3.07.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on C4 Therapeutics in a research note on Friday, October 9th. They issued an “overweight” rating and a $10.00 target price for the company. Finally, Lake Street Capital started coverage on C4 Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $11.00 target price for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.33.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.

C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.